Cytokine primed regenerative cells for treatment of ovarian failure

Abstract

Disclosed are novel means of generating cells uniquely suited for treatment of ovarian failure. In one embodiment regenerative cells are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment regenerative cells are cultured with primed plasma extracts. In another embodiment, regenerative cells are cultured under hypoxic conditions together with cytokines prior to administration to an individual. Regenerative cells useful for the current invention including mesenchymal and hematopoietic stem cells, as well as various growth factor producing cells.

1 . A method of augmenting efficacy of regenerative cells for repair of ovarian cells and/or tissues, comprising the steps of contacting regenerative cells with one or more biologically active substances; and/or incubating the regenerative cells under conditions to enhance efficacy of said regenerative cells for ovarian repair. 
     
     
         2 . The method of  claim 1 , wherein said cytokine comprises one or more growth factors. 
     
     
         3 . The method of  claim 2 , wherein said growth factor is interleukin-10. 
     
     
         4 . The method of  claim 2 , wherein said growth factor is HGF. 
     
     
         5 . The method of  claim 2 , wherein said growth factor is FGF-beta. 
     
     
         6 . The method of  claim 2 , wherein said growth factor is a member of the TGF-beta family. 
     
     
         7 . The method of  claim 2 , wherein said growth factor is IGF. 
     
     
         8 . The method of  claim 2 , wherein said growth factor is CTGF. 
     
     
         9 . The method of  claim 1 , wherein said biologically active substance comprises platelet rich plasma. 
     
     
         10 . The method of  claim 1 , wherein said regeneration comprises immune modulation. 
     
     
         11 . The method of  claim 1 , wherein the fibroblast cells are selected from the group consisting of (a) regenerative cell obtained by biopsy, cultured and proliferated; and (b) subsets thereof having greater ability to differentiate. 
     
     
         12 . The method of  claim 1 , wherein said regenerative cells are comprised in a pharmaceutically acceptable carrier selected from the group consisting of sterile solutions, hydrogels, implantable cell matrices, devices and a combination thereof. 
     
     
         13 . The method of  claim 1 , wherein the regenerative cells are derived from tissues selected from the group consisting of: skin, heart, blood vessels, bone marrow, skeletal muscle, liver, pancreas, brain, adipose tissue, foreskin, placental, and umbilical cord. 
     
     
         14 . The method of  claim 1 , wherein said biologically active substance is a protease. 
     
     
         15 . The method of  claim 1 , wherein said biologically active substance is a matrix metalloprotease. 
     
     
         16 . The method of  claim 1 , wherein said cell population is allogeneic. 
     
     
         17 . The method of  claim 1 , wherein said cell population is xenogenic. 
     
     
         18 . The method of  claim 1 , wherein said cell population is mesenchymal stem cells. 
     
     
         19 . The method of  claim 18 , wherein said mesenchymal stem cells express IL-1 receptor antagonist when treated with interferon gamma. 
     
     
         20 . The method of  claim 1 , wherein said regenerative cells are administered together with a growth factor.